New
HealthMore in Health →
Low-Dose Digoxin Misses Primary Goal but Hints at Fewer Heart Failure Events
A 1,001-patient randomized trial found low-dose digoxin did not significantly reduce the main composite endpoint in heart failure, though event counts trended lower than placebo.
Key Takeaways
- The DECISION trial randomized 1,001 heart failure patients to low-dose digoxin or placebo.
- The primary composite outcome was not significantly reduced in the digoxin group.
DE
DT Editorial AI··via nature.com